FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma
esmo - Evidence for efficacy is based on the results from the LITESPARK-022 study
AI Summary: Regulators have cleared the combination of belzutifan and pembrolizumab as adjuvant therapy for renal cell carcinoma at high risk of recurrence after nephrectomy. Clinical data showed improved disease‑free survival versus control, offering a new post‑surgery option intended to delay recurrence in patients with residual recurrence risk.
Related Stories
Bristol Myers Squibb wins first-in-class approval for protein‑degrader myeloma therapy / 25 days
FDA greenlights datopotamab deruxtecan for metastatic TNBC / 2 months
FDA approves belzutifan (Welireg) plus pembrolizumab for adjuvant RCC / 2 months
FDA clears first all-oral regimen for certain newly diagnosed AML patients / 3 months
VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 3 months
FDA expands approval of Lu‑177 radiopharmaceutical for prostate cancer / 4 wks
FDA clears Trodelvy alone and with Keytruda for first-line TNBC / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Healthcare, Supplements, Diabetes, Pediatric Oncology and look for the RSS link.
StackHealth Time Machine